QC: No

Amendment Tool v1.6 06 December 2021

ction 1: Project information											
Short project title*:	MAPS-2										
IRAS project ID* (or REC reference if no IRAS project ID is available):	290474										
Sponsor amendment reference number*:	MA-20-24										
Sponsor amendment date* (enter as DD/MM/YY):	02 May 2024										
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	A request is being m 6 follow up assessme 1. add date of form c 2. add date of discha 3. additional sections if more than one.	ent. The changes a completion. arge from hospital.	are:								
				Specific st	udy						
Project type (select):				Research ti	issue bank						
				Research o	latahase						
Has the study been reviewed by a UKECA-recognised Res	v	'es	. 1000011011	No							
Committee (REC) prior to this amendment?:				MIGNICS							
What type of UKECA-recognised Research Ethics Commit is applicable? (select):	ttee (REC) review			NHS/HSC I	KEU						
	Ministry of Defence (MoDRE										
Is all or part of this amendment being resubmitted to the Ro Committee (REC) as a modified amendment (i.e. a subst amendment previously given an unfavourable opinion)?	Y	'es	No								
Where is the NHS/HSC Research Ethics Committee (REC	that reviewed	England	Wales	Scotland	Northern Ireland						
the study based?:	,	Yes	No	No	No						
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	product (CTIMP)	Yes No									
EudraCT number*:		2021-003853-4	40								
Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service as the Combined Ways of Working (CWoW) pilot)?:			Yes		No						
Did the study receive Pharmacy Assurance?:			Yes		No						
Was the study a clinical investigation or other study of a modes the amendment make it one?:	edical device OR	Y	'es		No						
Did the study involve the administration of radioactive subsrequiring ARSAC review, OR does the amendment introdu		Y	'es	No							
Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances) amendment introduce this?:	•	Y	'es		No						
Did the study involve adults lacking capacity OR does the a introduce this?:	amendment	Y	'es	No							
Did the study involve access to confidential patient informal direct care team without consent OR does the amendment		Y	'es	No							
Did the study involve prisoners or young offenders who are supervised by the probation service OR does the amendmenthis?:		Y	′es	No							
Did the study involve children OR does the amendment int	roduce this?:	Y	'es	No							
Did the study involve NHS/HSC organisations prior to this a	amendment?:	Y	'es		No						
Did the study involve non-NHS/HSC organisations OR doe amendment introduce them?:	s the	Y	'es		No						
a	<u> </u>	England	Wales	Scotland	Northern Irelan						
Lead nation for the study:		Yes	No	No	No						
Which nations had participating NHS/HSC organisations pr	rior to this	Yes	Yes	Yes	Yes						
amendment?		162	103								

Section 2: Summary of change(s) Chief Investigator Sponsor Group Administrative

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Project information

	Change 1									
Area of change (select)*:	Study Documents									
Specific change (select - only available when area of change is selected first)*:	Other minor change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below									
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	Add following text to p 1. add date of form cc 2. add date of dischar 3. additional empty se readmissions if more	empletion. The general from hospital. The ections added to en	ant to report numerous hospital							
Applicability:		England	Wales	Scotland	Northern Ireland					
Where are the participating NHS/HSC organisations located by this change?*:	Yes	Yes	Yes	Yes						
Will all participating NHS/HSC organisations be affected by the some? (please note that this answer may affect the categorichange):	А	All	Some							
				Add anot	nother change					

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Alison Thorpe
Email address*:	sponsor@nottingham.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, amendments to trials processed under the combined review service should be made using the new part of IRAS. Further information can be found on the "Submission Guidance" tab.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

								F	Review	bodie	S								
			UK v	vide:			Eng	land a	nd Wa	ales:		Scot	land:		No	ortherr	n Irelar	nd:	
	REC	competent Authority IHRA - Medicines	Sompetent Authority JHRA - Devices	RSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	ВРР	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	risons	National coordinating function	Category
Change 1:	E	0 2	0 4	ď	Ľ.	(Y)	Ľ	0		(Y)	L.	Д	0)	(Y)			Д	(Y)	С
Overall reviews for the	amendment:																		

Full review:						N				N			N		N
Notification only:						Υ				Υ			Υ		Υ
Overall amendment type:	No	Non-substantial, no study-wide review required													
Overall Category:	С														